Novel method versus the Friedewald method for estimating low-density lipoprotein cholesterol in determination of the eligibility for statin treatment for primary prevention in the United States
| Autor: | Doosup Shin, Kullatham Kongpakpaisarn, Chandrashekar Bohra |
|---|---|
| Rok vydání: | 2018 |
| Předmět: |
Adult
Male medicine.medical_specialty Statin National Health and Nutrition Examination Survey medicine.drug_class primary prevention Population Eligibility Determination Observational Study Low density lipoprotein cholesterol 030204 cardiovascular system & hematology 03 medical and health sciences 0302 clinical medicine Primary prevention Internal medicine Humans Medicine 030212 general & internal medicine education Aged low-density lipoprotein cholesterol education.field_of_study business.industry Atherosclerotic cardiovascular disease the Friedewald method statin General Medicine Middle Aged Statin treatment Nutrition Surveys United States Confidence interval Lipoproteins LDL Cross-Sectional Studies Cardiovascular Diseases ComputingMethodologies_DOCUMENTANDTEXTPROCESSING Female novel method Hydroxymethylglutaryl-CoA Reductase Inhibitors business Research Article |
| Zdroj: | Medicine |
| ISSN: | 0025-7974 |
| DOI: | 10.1097/md.0000000000010612 |
| Popis: | Supplemental Digital Content is available in the text Although the Friedewald method has been used as the clinical standard to estimate low-density lipoprotein cholesterol (LDL-C) levels, a novel method with better accuracy was suggested and is now being adopted in real practice. We investigated the effect of this novel method on determining the eligibility for statin treatment for primary prevention in the United States. In this cross-sectional study, we determined the discordance in the statin-eligible population for primary prevention according to the 2 different LDL-C estimating methods based on the 2013 American College of Cardiology/American Heart Association (ACC/AHA) guidelines. Using data from the National Health and Nutrition Examination Survey 2005–2014, we included 5302 nationally representative US adults aged between 40 and 75 years without history of atherosclerotic cardiovascular disease (ASCVD). Sampling weights were used in all statistical analyses to account for complex sampling design and nonresponse. If the Friedewald method is replaced by the novel method for analysis of the fasting samples, 0.2% (95% confidence interval [CI], 0.0–0.8) and 0.4% (95% CI, 0.3–0.6) of the population would no longer be eligible or would become newly eligible for statin treatment, respectively. Among the individuals with a TG level ≥150 mg/dL and LDL-C level estimated using the Friedewald method |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|